Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity: The Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ)

Roma Maguire, Grigorios Kotronoulas, Peter Donnan, Lisa McCann, Catherine Paterson, John Connaghan, David Di Domenico, Nora Kearney

Research output: Contribution to journal › Article

1 Citation (Scopus)

Abstract

Close monitoring of chemotherapy toxicity can be instrumental in ensuring prompt symptom management and quality care. Our aim was to develop a brief clinical tool to enable daily assessment of chemotherapy toxicity, and investigate/establish its content validity, feasibility/applicability, internal consistency and stability. Development of the Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ) was based on an initial item pool created from two scoping reviews. Expert panel review (n=15) and cognitive debriefing with patients with cancer (n=7) was used to establish content validity. Feasibility/acceptability, applicability (self-report v. interviewlike administration), internal consistency (KR-20) and test-retest reliability (at 1-hour intervals) of the DCTAQ were field-tested with 82 patients with breast or colorectal cancer receiving active chemotherapy at eight hospitals. Initial development/content validity stages enabled item revisions and re-wording that led to a final, 11-item DCTAQ version with 10 core symptom items plus one open-ended ‘any other symptom’ item. Feasibility and acceptability were demonstrated through absence of participant withdrawals, absence of missing data and no complaints about tool length. The DCTAQ was found to have modest internal consistency (KR-20=0.56), but very good test-retest reliability. The DCTAQ is a brief clinical tool that allows for rapid and accurate daily assessments of chemotherapy toxicity in clinical practice.
LanguageEnglish
JournalEuropean Journal of Cancer Care
Publication statusPublished - 11 Jul 2018

Fingerprint

Drug Therapy
Reproducibility of Results
Surveys and Questionnaires
Self-Assessment
Quality of Health Care
Self Report
Colorectal Neoplasms
Breast Neoplasms
Neoplasms

Keywords

  • patient-reported outcomes
  • cancer
  • chemotherapy toxicity
  • Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ)
  • reliability
  • validity

Cite this

Maguire, Roma ; Kotronoulas, Grigorios ; Donnan, Peter ; McCann, Lisa ; Paterson, Catherine ; Connaghan, John ; Di Domenico, David ; Kearney, Nora. / Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity : The Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ). In: European Journal of Cancer Care. 2018.
@article{445cbd5b5ab5444ca3ad9e0cf7e28fa0,
title = "Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity: The Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ)",
abstract = "Close monitoring of chemotherapy toxicity can be instrumental in ensuring prompt symptom management and quality care. Our aim was to develop a brief clinical tool to enable daily assessment of chemotherapy toxicity, and investigate/establish its content validity, feasibility/applicability, internal consistency and stability. Development of the Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ) was based on an initial item pool created from two scoping reviews. Expert panel review (n=15) and cognitive debriefing with patients with cancer (n=7) was used to establish content validity. Feasibility/acceptability, applicability (self-report v. interviewlike administration), internal consistency (KR-20) and test-retest reliability (at 1-hour intervals) of the DCTAQ were field-tested with 82 patients with breast or colorectal cancer receiving active chemotherapy at eight hospitals. Initial development/content validity stages enabled item revisions and re-wording that led to a final, 11-item DCTAQ version with 10 core symptom items plus one open-ended ‘any other symptom’ item. Feasibility and acceptability were demonstrated through absence of participant withdrawals, absence of missing data and no complaints about tool length. The DCTAQ was found to have modest internal consistency (KR-20=0.56), but very good test-retest reliability. The DCTAQ is a brief clinical tool that allows for rapid and accurate daily assessments of chemotherapy toxicity in clinical practice.",
keywords = "patient-reported outcomes, cancer, chemotherapy toxicity , Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ), reliability, validity",
author = "Roma Maguire and Grigorios Kotronoulas and Peter Donnan and Lisa McCann and Catherine Paterson and John Connaghan and {Di Domenico}, David and Nora Kearney",
year = "2018",
month = "7",
day = "11",
language = "English",
journal = "European Journal of Cancer Care",
issn = "0961-5423",

}

Maguire, R, Kotronoulas, G, Donnan, P, McCann, L, Paterson, C, Connaghan, J, Di Domenico, D & Kearney, N 2018, 'Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity: The Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ)' European Journal of Cancer Care.

Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity : The Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ). / Maguire, Roma; Kotronoulas, Grigorios; Donnan, Peter; McCann, Lisa; Paterson, Catherine; Connaghan, John; Di Domenico, David; Kearney, Nora.

In: European Journal of Cancer Care, 11.07.2018.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity

T2 - European Journal of Cancer Care

AU - Maguire, Roma

AU - Kotronoulas, Grigorios

AU - Donnan, Peter

AU - McCann, Lisa

AU - Paterson, Catherine

AU - Connaghan, John

AU - Di Domenico, David

AU - Kearney, Nora

PY - 2018/7/11

Y1 - 2018/7/11

N2 - Close monitoring of chemotherapy toxicity can be instrumental in ensuring prompt symptom management and quality care. Our aim was to develop a brief clinical tool to enable daily assessment of chemotherapy toxicity, and investigate/establish its content validity, feasibility/applicability, internal consistency and stability. Development of the Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ) was based on an initial item pool created from two scoping reviews. Expert panel review (n=15) and cognitive debriefing with patients with cancer (n=7) was used to establish content validity. Feasibility/acceptability, applicability (self-report v. interviewlike administration), internal consistency (KR-20) and test-retest reliability (at 1-hour intervals) of the DCTAQ were field-tested with 82 patients with breast or colorectal cancer receiving active chemotherapy at eight hospitals. Initial development/content validity stages enabled item revisions and re-wording that led to a final, 11-item DCTAQ version with 10 core symptom items plus one open-ended ‘any other symptom’ item. Feasibility and acceptability were demonstrated through absence of participant withdrawals, absence of missing data and no complaints about tool length. The DCTAQ was found to have modest internal consistency (KR-20=0.56), but very good test-retest reliability. The DCTAQ is a brief clinical tool that allows for rapid and accurate daily assessments of chemotherapy toxicity in clinical practice.

AB - Close monitoring of chemotherapy toxicity can be instrumental in ensuring prompt symptom management and quality care. Our aim was to develop a brief clinical tool to enable daily assessment of chemotherapy toxicity, and investigate/establish its content validity, feasibility/applicability, internal consistency and stability. Development of the Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ) was based on an initial item pool created from two scoping reviews. Expert panel review (n=15) and cognitive debriefing with patients with cancer (n=7) was used to establish content validity. Feasibility/acceptability, applicability (self-report v. interviewlike administration), internal consistency (KR-20) and test-retest reliability (at 1-hour intervals) of the DCTAQ were field-tested with 82 patients with breast or colorectal cancer receiving active chemotherapy at eight hospitals. Initial development/content validity stages enabled item revisions and re-wording that led to a final, 11-item DCTAQ version with 10 core symptom items plus one open-ended ‘any other symptom’ item. Feasibility and acceptability were demonstrated through absence of participant withdrawals, absence of missing data and no complaints about tool length. The DCTAQ was found to have modest internal consistency (KR-20=0.56), but very good test-retest reliability. The DCTAQ is a brief clinical tool that allows for rapid and accurate daily assessments of chemotherapy toxicity in clinical practice.

KW - patient-reported outcomes

KW - cancer

KW - chemotherapy toxicity

KW - Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ)

KW - reliability

KW - validity

UR - https://onlinelibrary.wiley.com/journal/13652354

M3 - Article

JO - European Journal of Cancer Care

JF - European Journal of Cancer Care

SN - 0961-5423

ER -

Maguire R, Kotronoulas G, Donnan P, McCann L, Paterson C, Connaghan J et al. Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity: The Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ). European Journal of Cancer Care. 2018 Jul 11.

Access to Document